BioMarin Eyes 11.6% Q1 Revenue Growth After 4.1% Q4 Sales Rise
BioMarin reported $776.1 million in Q4 revenue, up 4.1% year-over-year, meeting analyst revenue targets but missing full-year EPS guidance. Wall Street projects Q1 sales to rise 11.6% year-over-year, down from last year’s 15.6% gain after multiple revenue shortfalls over two years.
1. Q4 Results and EPS Guidance Miss
BioMarin posted $776.1 million in Q4 revenue, up 4.1% year-over-year, meeting analyst revenue targets but missing full-year EPS guidance and quarterly EPS estimates.
2. Q1 Revenue Forecast
Analysts forecast an 11.6% increase in Q1 revenue, slowing from the 15.6% growth recorded in the same quarter a year earlier.
3. Analyst Estimates and Historical Performance
Estimates have remained steady over the past month, reflecting confidence in the outlook, yet BioMarin has missed revenue expectations multiple times in the last two years.
4. Peer Comparisons and Stock Performance
Peers in the therapeutics segment reported mixed results: Biogen saw 1.2% sales growth and Halozyme 51.6%, while BioMarin’s shares rose 13.9% in the past month versus a 3.2% decline for the group, with an average analyst price target of $88.87.